Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Oppenheimer issued their FY2021 EPS estimates for shares of Sunesis Pharmaceuticals in a research note issued on Thursday. Oppenheimer analyst H. Singh expects that the biopharmaceutical company will earn ($0.42) per share for the year. Oppenheimer has a “Buy” rating and a $7.00 price objective on the stock.
A number of other analysts have also commented on the company. Wells Fargo & Co lowered Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $2.70 to $2.00 in a research note on Tuesday, December 5th. Cantor Fitzgerald set a $3.00 price target on Sunesis Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, December 11th. ValuEngine lowered Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Finally, UBS Group began coverage on Sunesis Pharmaceuticals in a research note on Monday, November 20th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Sunesis Pharmaceuticals has an average rating of “Hold” and an average price target of $4.00.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) traded down $0.61 during mid-day trading on Monday, hitting $3.63. The stock had a trading volume of 1,345,869 shares, compared to its average volume of 286,268. Sunesis Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $7.69. The firm has a market capitalization of $139.63, a price-to-earnings ratio of -2.79 and a beta of 1.39. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.08.
Several institutional investors have recently bought and sold shares of SNSS. Wells Fargo & Company MN lifted its stake in shares of Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 18,254 shares during the period. Geode Capital Management LLC lifted its stake in shares of Sunesis Pharmaceuticals by 105.2% in the fourth quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 64,343 shares during the period. BlackRock Inc. lifted its stake in shares of Sunesis Pharmaceuticals by 9.5% in the fourth quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 11,351 shares during the period. Vatera Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals in the fourth quarter worth approximately $673,000. Finally, Vanguard Group Inc. lifted its stake in shares of Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after acquiring an additional 23,819 shares during the period. 53.20% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Analysts Offer Predictions for Sunesis Pharmaceuticals, Inc.’s FY2021 Earnings (SNSS)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/analysts-offer-predictions-for-sunesis-pharmaceuticals-inc-s-fy2021-earnings-snss.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.